





BMJ Open Remote versus face-to-face home-based exercise programme in people with amyotrophic lateral sclerosis: protocol for a randomised clinical trial

Aline Alves de Souza ^{1,2}, Stephano Tomaz da Silva ^{1,2},
Karen de Medeiros Pondofe ^{1,2}, Vanessa Regiane Resqueti,^{1,2}
Luciana Protásio de Melo,² Ricardo Alexandro de Medeiros Valentim,²
Tatiana Souza Ribeiro ^{1,2}

To cite: Souza AA, Silva ST, Pondofe KM, *et al*. Remote versus face-to-face home-based exercise programme in people with amyotrophic lateral sclerosis: protocol for a randomised clinical trial. *BMJ Open* 2022;**12**:e056323. doi:10.1136/bmjopen-2021-056323

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-056323>).

Received 17 August 2021
Accepted 24 April 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Physical Therapy, Federal University of Rio Grande do Norte, Natal, Brazil

²Laboratory of Technological Innovation in Health, Federal University of Rio Grande do Norte, Natal, Brazil

Correspondence to

Aline Alves de Souza;
alvss.aline@gmail.com

ABSTRACT

Introduction Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with variable and complex clinical manifestations that requires a multidisciplinary approach. However, face-to-face treatment in this population may experience barriers, such as difficulty accessing physical therapists or other professionals. As a result, strategies (eg, telerehabilitation) emerged to facilitate treatment and physical therapy monitoring. This study aims to evaluate the effects of remote versus face-to-face home-based exercise programmes on clinical outcomes and treatment adherence of people with ALS.

Methods and analysis This is a single-blind randomised clinical trial protocol that will include 44 people with clinical diagnosis of ALS at any clinical stage and aged between 18 and 80 years. Participants will be randomised into two groups after face-to-face evaluation and perform a home-based exercise programme three times a week for 6 months. A physical therapist will monitor the exercise programme once a week remotely (phone calls—experimental group) or face-to-face (home visits—control group). The primary outcome measure will be functional capacity (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised). Secondary outcomes will include disease severity (Amyotrophic Lateral Sclerosis Severity Scale), fatigue (Fatigue Severity Scale), pain (Visual Analogue Scale and body pain diagram), adverse events and adherence rate. Outcomes will be initially evaluated face-to-face and reevaluated remotely every 2 months and 1 month after interventions. Linear mixed models will compare outcome measures between groups and evaluations ($\alpha=5\%$).

Ethics and dissemination This study was approved by the research ethics committee of Hospital Universitário Onofre Lopes/Universidade Federal do Rio Grande do Norte (no. 3735479). We expect to identify the effects of an exercise programme developed according to ALS stages and associated with remote or face-to-face monitoring on clinical outcomes using revaluations and follow-up after interventions.

Trial registration number Brazilian Registry Clinical Trials (RBR-10z9pgfv).

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Single-blind randomised clinical trial.
- ⇒ Clinically important outcomes.
- ⇒ Specific home-based exercises for each stage of amyotrophic lateral sclerosis (ALS).
- ⇒ Analysis of face-to-face versus remote exercise monitoring.
- ⇒ The rapid evolution of ALS may hinder long-term monitoring.

INTRODUCTION

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of upper and lower motor neurons.¹ The clinical manifestation may include limb (eg, muscle weakness, fasciculations, reduced movement speed and muscle atrophy) or bulbar symptoms (eg, facial muscle weakness, respiratory disorders, dysphagia and dysarthria), which may lead to death due to respiratory failure.^{2,3} Muscle weakness is progressive from the initial stages and reduces functional performance and quality of life.⁴

A multidisciplinary approach is essential for the effectiveness of interventions due to disease complexity, and physical therapy is an important component of this approach.¹ Individualised physical therapy is generally prescribed to delay progressive impairments and maintain the functionality of people with ALS.⁵

Physical exercise benefits people with ALS and improves functional independence and quality of life.^{6–8} When appropriately prescribed, physical exercise also promotes physiological and psychological benefits in this population.⁹ Although one can affirm that active exercise causes fatigue by overuse,

**Table 1** Proposed exercise protocol according to disease stage

Stage	Exercises
0 (no impairment or very mild impairment)	Aerobic, resistance and stretching exercises
1 (mild impairment)	Aerobic, resistance or active-assisted and stretching exercises
2 (mild to moderate impairment)	Aerobic, resistance (unaffected muscles), active or active-assisted (affected muscles) and stretching exercises
3 (moderate impairment)	Aerobic (if possible), active-assisted, passive mobilisation and stretching exercises
4 (moderate to severe impairment)	Stretching and passive or active-assisted mobilisation

its benefits on muscle weakness and atrophy by disuse must be strongly considered.¹⁰

Literature regarding physical therapy programmes for improving motor function of people with ALS is scarce.^{7,8} However, resistance and aerobic exercises may be useful to these patients, especially in the middle stage of the disease.⁷ Active or assistive exercises, passive exercises and stretching exercises have also been considered in the middle and advanced stages.⁵

In the rehabilitation context, difficult access to health services reduces adherence of people with ALS,¹¹ which may lead to the advent of new strategies (eg, telerehabilitation). Telerehabilitation consists of remote evaluation, monitoring, health education and exercise intervention.¹² This strategy prevents displacement (relevant for patients with limited mobility), reduces costs and time, and provides convenient and flexible scheduling.¹²

Adherence to telerehabilitation may vary among patients and types of intervention and monitoring.¹³ A high rate of non-adherence was observed in people with Parkinson's disease when exercises were performed at home without face-to-face supervision.¹⁴ Conversely, another study conducted with the same population observed that face-to-face programmes with minimal supervision (ie, once a week) improved participant engagement.¹⁵

Face-to-face follow-up by physical therapists may positively influence time, frequency and correct execution of exercises.¹⁶ In contrast, home-based exercises prescribed by the therapist and performed at home without professional supervision stimulate self-management and improve performance.^{17,18} Patients under remote monitoring are expected to contact therapists more frequently, allowing the team to conduct individualised therapy.¹⁸ Nevertheless, remote and face-to-face treatment and monitoring are possibly equivalent when considering scientific evidence, professional experience, and patient preference.¹⁷

Although evidence regarding telerehabilitation for ALS is limited, studies suggest it as an alternative approach, especially for patients with difficult access to health

services.^{19,20} Evidence from other neurological conditions (ie, stroke) suggests that telerehabilitation is not inferior and has a lower cost for implementation than face-to-face rehabilitation.²¹

Considering the benefits of physical exercise and the need of patients with ALS for full-time care, this study aims to evaluate the effects of face-to-face versus remote home-based exercise programmes on functional capacity, fatigue, disease severity, pain and treatment adherence of people with ALS.

METHODS

Study design

This is a single-blind randomised clinical trial protocol developed according to the Standard Protocol Items: Recommendations for Interventional Trials.²²

Participants

This study will include definite, probable or possible participants with ALS of both sexes, diagnosed by a neurologist (*El Escorial*²³ criteria), aged between 18 and 80 years, and able to understand and perform simple motor instructions according to verbal commands. Bedridden participants under continuous use of non-invasive ventilation and those who need but do not have caregivers available will be excluded from the study.

Recruitment

Participants will be recruited and initially evaluated at the Ambulatory of Neuromuscular Diseases of the Onofre Lopes University Hospital (Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil). Demographic and clinical data (ie, age, weight, sex, marital status, symptom onset, date of diagnosis, initial symptom, chief complaint, dominant side and most affected site) will be collected, and a trained physical therapist blinded to allocation of experimental and control groups will assess functional physical capacity, disease severity, fatigue and pain. Participant enrolment will occur between November 2021 and December 2022.

Randomisation and allocation concealment

An external researcher will randomise participants into two groups (ie, experimental and control) of 22 participants each using the website www.randomization.com. A restricted randomisation with four blocks of eight and two blocks of six participants will be used. The same researcher will maintain the randomised sequence in numbered and sealed envelopes and keep it confidential until the end of the study. Therapists will open envelopes only before the training of each participant. Therapists and participants will not be blinded due to intervention characteristics, whereas researchers responsible for statistical analyses will be blinded. Also, participants will not be informed about interventions applied to the other group.

Intervention groups

After the initial evaluation, a trained physical therapist will teach exercises to participants and caregivers,

Box 1 Supervision questionnaire to monitor exercise performance

Monitoring questionnaire

- ⇒ How many times a week (how often) did you perform the exercises?
- ⇒ Did you have any difficulties performing the movements?
- ⇒ Did you feel the need to take a break to rest? If yes, how many times and for how long?
- ⇒ Did you feel muscle fatigue, pain, discomfort, shortness of breath or any other symptom during or after exercises?
- ⇒ Did you feel the need to use non-invasive ventilation before, during or right after the exercises?

according to disease stage (table 1). The proposed exercises will be tested with the participant and adjusted to ensure a correct execution. Participants and caregivers from experimental (EG) and control groups (CG) will also receive a guideline with type, frequency and duration of exercises. Participants of both groups will perform the same home-based exercise programme with specific exercises for each stage of the disease, three times a week, for 6 months, and with the assistance of caregivers.

A physical therapist will conduct face-to-face (visits—EG) or remote (phone calls, video calls or instant messaging app—CG) monitoring of exercises once a week and apply a questionnaire regarding exercise frequency and fatigue after the exercise programme (box 1). Therapists will also answer questions from participants and caregivers and adjust the protocol according to individual responses if needed (eg, changes in load or rest between series).

Participants are currently monitored by a multidisciplinary team of the ambulatory, including a neurologist, physiotherapist, speech therapist, nutritionist, psychologist and nurse. We will record all therapies performed by professionals of the multidisciplinary team and external professionals (eg, respiratory and occupational therapists) and instruct participants to maintain activities throughout the study.

The non-adherence to the programme will be considered if participants do not perform exercises for more than three consecutive days or do not answer phone calls for more than four consecutive days. In the case of adverse events interfering with or caused by exercises (eg, pain, discomfort or falls), patients will be instructed to temporarily suspend the proposed exercise programme and communicate to the therapist responsible for the monitoring. In this case, guidance on managing the condition will be provided.

Statistical analyses

Sample size

Sample size was calculated using an online calculator²⁴ (www.openepi.com) and considering functional capacity as the primary outcome, assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-r). A similar study²⁵ showed a mean functional capacity of 32.8±6.5 and 28.7±7.5 in the EG and CG, respectively, after 6 months of intervention. Based on

these data, a sample size of 18 participants per group (total n=36) was estimated to detect a 20% difference between groups ($\alpha=5\%$ and 80% of statistical power). A final sample size of 22 participants per group (total n=44) was calculated considering a loss of approximately 20%.

Statistical analysis

Statistical Package for the Social Sciences software V.22 (IBM Corp) will be used for data analysis, and Shapiro-Wilk test will verify data normality. Descriptive statistics will be conducted for sample characterisation, and inferential statistics will consider an alpha of 5%. Linear mixed models will compare outcome measures between groups and evaluation times. In the case of statistical significance, the Bonferroni post hoc test will be applied to identify differences. Intention-to-treat analysis will be considered to analyse participants according to groups. Additionally, data loss will be inferred by repeating values of the previous evaluation.

Patients and public involvement

The public or participants were not involved in planning recruitment and conducting processes. However, we intend to involve participants in the disclosure plan of this study.

OUTCOMES

Outcomes will be evaluated initially face-to-face and reevaluated remotely every 2 months during interventions and 1 month after the rehabilitation programme.

Primary outcome

Functional capacity

The ALSFRS-r, validated for the Brazilian population,²⁶ will assess functional physical capacity to perform activities during an interview with participants or caregivers (in case of impaired speech). This scale is reliable²⁷ and has 12 items ranging from 0 to 4 points (maximum score of 48 points, higher scores indicate a better functionality). Participants will be classified according to a reduction in the total score, considering 30 points as cut-off (≤ 30 and >30) and 20%–25% change in ALSFRS-r slope as clinically significant.^{27 28}

The ALSFRS-r will also be used to assess disease progression concerning physical capacity. The rate of disease progression (Δ PR) will be calculated by subtracting the total ALSFRS-r score between assessments and dividing by time (in months) since the baseline assessment.²⁹ ALSFRS-r progression will be classified as slow (Δ PR ≤ 0.5), intermediate ($0.5 \leq \Delta$ PR ≤ 1) or fast (Δ PR ≥ 1), and analyses will be adjusted for the rate of progression.

Secondary outcomes

Disease severity

The Amyotrophic Lateral Sclerosis Severity Scale is a reliable and valid nominal scale used to classify disease severity by identifying the functional independence level of individuals.^{30 31} It has four categories (lower extremity,

TIMEPOINT**	STUDY PERIOD					
	Enrollment	Allocation	Post-allocation			Close-out
	-t ₁	0	t ₁	t ₂	t ₃	t ₄
ENROLMENT:						
Eligibility screening	X					
Informed consent	X					
Allocation		X				
INTERVENTIONS:						
Control Group			←————→			
Experimental Group			←————→			
ASSESSMENTS:						
Sociodemographic data	X					
Cognition	X					
Functional Capacity	X		X	X	X	X
Disease severity	X		X	X	X	X
Fatigue	X		X	X	X	X
Pain	X		X	X	X	X
Adverse events			X	X	X	
Adherence rate			X	X	X	

Figure 1 Study schedule. -t₁ (initial evaluation); t₁ (after 2 months); t₂ (after 4 months); t₃ (after 6 months); t₄ (1 month after interventions).

upper extremity, speech and swallowing) with scores ranging from 1 to 10, considering a decline in function, functional adaptation, auxiliary devices and need for caregiver. The total score ranges from 4 (worst function) to 40 (normal function).³¹

Fatigue

The Fatigue Severity Scale (FSS) is not specific to assess participants with ALS; however, it has acceptable validity and reliability for some neuromuscular conditions³² and is commonly used to assess fatigue.^{33 34} FSS is composed of nine statements influenced by fatigue (eg, motivation, performance, carrying out duties and responsibilities, work, family and social life), in which patients select a score (1–7) that best describes the agreement level for each statement.³⁵ Total scores range from 9 to 63, and scores ≥28 indicate fatigue.³⁶

Although FSS may not be sensitive to detect changes in our ALS population, the literature indicates that a 1.9-point difference in total score would reflect a clinically important change.³²

Pain

Pain intensity will be assessed during static position (static pain) and movement (dynamic pain) using the Visual Analogue Scale (VAS).³⁷ VAS is a valid and reliable instrument used in studies with people with ALS, and scores range from 0 (no pain) to 10 (maximum supported pain).³⁸ Additionally, a body pain diagram will determine the pain location reported by participants. This tool provides a reliable representation of 45 body areas where patients can indicate specific painful body areas.³⁹

Adverse events

Adverse events will be self-reported weekly during face-to-face or remote monitoring (see [Box 1](#)). These adverse events will be classified according to disease severity, and potential associations with the exercise programme will be determined.

Adherence rate

Adherence to the intervention will be calculated using the percentage of participants that performed the entire exercise programme (6 months) at least once a week. [Figure 1](#) shows the study schedule.

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

This project was approved by the research ethics committee of HUOL/UFRN (no. 3735479), according to Resolution 466/12 of the National Health Council and Declaration of Helsinki. Researchers will invite patients and caregivers to participate voluntarily and sign the informed consent form (see online supplemental file 1) to be included in the study.

Consent for publication and confidentiality

Information of all participants will be kept confidential and stored in the laboratory database. Only researchers will access the database, ensuring anonymity, respect and human dignity. Results will be published in peer-reviewed journals and presented at scientific meetings. In case of significant changes in the protocol, we will inform participants, the Brazilian Registry of Clinical Trials and journals. If requested, we will provide a copy of the informed consent form.

Availability of protocol and data

The protocol information is registered and available. The corresponding author will provide the study protocol and data of participants on reasonable request to achieve study goals.

DISCUSSION

Participants need specific and continuous healthcare from the early stages of ALS due to the fast disease progression. This specific healthcare is challenging for rehabilitation professionals, mainly because of difficulties regarding healthcare access. Displacement to treatment centres demands time and funds from the government and participants. Therefore, effective home-based low-cost treatments (eg, physical exercise) should be considered the first choice in rehabilitation programmes.

We expect this study demonstrates the usefulness and applicability of telerehabilitation for patients with ALS, reinforcing the benefits of home-based exercises and remote monitoring. Regarding study limitations, the fast disease progression may lead to sudden complications or death and limit the long-term follow-up of participants.

Twitter Karen de Medeiros Pondofe @karenpondofe and Vanessa Regiane Resqueti @vanessaesqueti

Acknowledgements The authors would like to thank the Laboratory of Technological Innovation in Health (LAIS) of the Federal University of Rio Grande do Norte. The authors thank Probatas Academic Services for providing scientific language translation, revision and editing.

Contributors AAS: research concept and study design, literature review, writing of the manuscript and reviewing. STS: literature review and study design. KMP: research concept and study design. VRR: research concept and study design. LPM: study design. RAMV: funding acquisition. TSR: research concept and study design, reviewing and project administration.

Funding This study was supported in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES)—Finance Code 001 and by the National Council for Scientific and Technological Development and Ministry of Health, through a Decentralized Execution Term (TED132/2018).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Aline Alves de Souza <http://orcid.org/0000-0002-4424-3034>
 Stephano Tomaz da Silva <http://orcid.org/0000-0002-4537-516X>
 Karen de Medeiros Pondofe <http://orcid.org/0000-0003-2105-1096>
 Tatiana Souza Ribeiro <http://orcid.org/0000-0002-9611-1076>

REFERENCES

- 1 EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, *et al*. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. *Eur J Neurol* 2012;19:360–75.
- 2 Xerez DR. Rehabilitation in amyotrophic lateral sclerosis: literature review. *Acta Fisiatrica* 2008;15:182–8.
- 3 Cirne GNM, Bezerra LAP, Cacho RO. Functional profile of ALS patients over 14 months of physical therapy. *Braz J Occup Ther* 2016;24:557–62.
- 4 Perrin C, Unterborn JN, Ambrosio Carolyn D, *et al*. Pulmonary complications of chronic neuromuscular diseases and their management. *Muscle Nerve* 2004;29:5–27.
- 5 Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. *Muscle Nerve* 2014;50:4–13.
- 6 Merico A, Cavinato M, Gregorio C. Effects of combined endurance and resistance training in amyotrophic lateral sclerosis: a pilot, randomized, controlled study. *Eur J Transl Myol* 2018;28:72–8.
- 7 Bello-Haas VD, Florence JM, Kloos AD, *et al*. A randomized controlled trial of resistance exercise in individuals with ALS. *Neurology* 2007;68:2003–7.
- 8 Clawson LL, Cudkowicz M, Krivickas L, *et al*. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 2018;19:250–8.



- 9 Bello-Haas VD. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights. *Degener Neurol Neuromuscul Dis* 2018;8:45–54.
- 10 Bello-Haas D V, Florence JM, Cochrane Neuromuscular Group. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database Syst Rev* 2013;68:CD005229.
- 11 Helleman J, Kruitwagen ET, van den Berg LH, *et al*. The current use of telehealth in ALS care and the barriers to and facilitators of implementation: a systematic review. *Amyotroph Lateral Scler Frontotemporal Degener* 2020;21:167–82.
- 12 van Egmond MA, van der Schaaf M, Vredevelde T, *et al*. Effectiveness of physiotherapy with telerehabilitation in surgical patients: a systematic review and meta-analysis. *Physiotherapy* 2018;104:277–98.
- 13 Hoas H, Andreassen HK, Lien LA, *et al*. Adherence and factors affecting satisfaction in long-term telerehabilitation for patients with chronic obstructive pulmonary disease: a mixed methods study. *BMC Med Inform Decis Mak* 2016;16:1–14.
- 14 Vasconcellos LSD, Silva RS, Pachêco TB. Telerehabilitation-based trunk exercise training for motor symptoms of individuals with Parkinson's disease: A randomized controlled clinical trial. *J Telemed Telecare* 2021;1357633X:211021740.
- 15 Flynn A, Allen NE, Dennis S, *et al*. Home-Based prescribed exercise improves balance-related activities in people with Parkinson's disease and has benefits similar to centre-based exercise: a systematic review. *J Physiother* 2019;65:189–99.
- 16 MTDS G, Vale VDD, Aoki T. The benefits of neurofunctional physiotherapy in patients with amyotrophic lateral sclerosis: a systematic review. *ABCS Health Sci*. 2016;41:84–9.
- 17 Fioratti I, Fernandes LG, Reis FJ, *et al*. Strategies for a safe and assertive telerehabilitation practice. *Braz J Phys Ther* 2021;25:113–6.
- 18 Chen Y-Y, Guan B-S, Li Z-K, *et al*. Application of telehealth intervention in Parkinson's disease: a systematic review and meta-analysis. *J Telemed Telecare* 2020;26:3–13.
- 19 Nijeweme-d'Hollosy WO, Janssen EPF, Huis in 't Veld RMHA, *et al*. Tele-treatment of patients with amyotrophic lateral sclerosis (ALS). *J Telemed Telecare* 2006;12 Suppl 1:31–4.
- 20 Hobson EV, Baird WO, Cooper CL, *et al*. Using technology to improve access to specialist care in amyotrophic lateral sclerosis: a systematic review. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:313–24.
- 21 Laver KE, Adey-Wakeling Z, Crotty M, *et al*. Telerehabilitation services for stroke. *Cochrane Database Syst Rev* 2020;2020:CD010255.
- 22 Chan A-W, Tetzlaff JM, Gøtzsche PC, *et al*. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
- 23 Brooks BR, Miller RG, Swash M, *et al*. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–9.
- 24 Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health, version: www.OpeEpi.com, updated 2013/04/06 [Accessed 2021/02/15].
- 25 Lunetta C, Lizio A, Sansone VA, *et al*. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. *J Neurol* 2016;263:52–60.
- 26 Guedes K, Pereira C, Pavan K, *et al*. Cross-Cultural adaptation and validation of ALS functional rating Scale-Revised in Portuguese language. *Arq Neuropsiquiatr* 2010;68:44–7.
- 27 Cedarbaum JM, Stambler N, Malta E, *et al*. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). *J Neurol Sci* 1999;169:13–21.
- 28 Castrillo-Viguera C, Grasso DL, Simpson E, *et al*. Clinical significance in the change of decline in ALSFRS-R. *Amyotroph Lateral Scler* 2010;11:178–80.
- 29 Kimura F, Fujimura C, Ishida S, *et al*. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. *Neurology* 2006;66:265–7.
- 30 NMFV L, Guerra CC, Teixeira LC. Translation and validation of the amyotrophic lateral sclerosis severity scale. *Phys Ther Rehabil Sci*. 2009;16:316–22.
- 31 Hillel AD, Miller RM, Yorkston K, *et al*. Amyotrophic lateral sclerosis severity scale. *Neuroepidemiology* 1989;8:142–50.
- 32 Learmonth YC, Dlugonski D, Pilutti LA, *et al*. Psychometric properties of the fatigue severity scale and the modified fatigue impact scale. *J Neurol Sci* 2013;331:102–7.
- 33 Ramirez C, Piemonte MEP, Callegaro D, *et al*. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. *Amyotroph Lateral Scler* 2008;9:75–80.
- 34 Lo Coco D, La Bella V, Fatigue LBV. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. *Eur J Neurol* 2012;19:760–3.
- 35 Toledo FO, Junior WM, Speciali JG, *et al*. Cross-cultural adaptation and validation of the Brazilian version of the Fatigue Severity Scale (FSS). In: *ISPOR 14th annual European Congress, 2011, Madrid (España)*. Baltimore, USA: Value in HealthElsevier, 2011; 14. A329–30.
- 36 Krupp LB, LaRocca NG, Muir-Nash J, *et al*. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46:1121–3.
- 37 Price DD, McGrath PA, Rafii A, *et al*. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. *Pain* 1983;17:45–56.
- 38 Adelman EE, Albert SM, Rabkin JG, *et al*. Disparities in perceptions of distress and burden in ALS patients and family caregivers. *Neurology* 2004;62:1766–70.
- 39 Southerst D, Stupar M, Côté P, *et al*. The reliability of measuring pain distribution and location using body pain diagrams in patients with acute whiplash-associated disorders. *J Manipulative Physiol Ther* 2013;36:395–402.

Consent Form

This is an invitation for you to participate in the research: “Project ReVELA: Effects of a home-based exercise protocol with remote and face-to-face monitoring of individuals with Amyotrophic Lateral Sclerosis: randomized clinical trial”, which has physiotherapist Aline Alves de Souza as the responsible researcher .

This research aims to compare the forms of monitoring, in person and remotely, of the home exercise protocol and the impact of these exercises on the levels of functional physical capacity, fatigue and pain in people with Amyotrophic Lateral Sclerosis (ALS).

The reason that leads us to carry out this study is the need for continuous care for people with ALS, especially with regard to the maintenance of physical capacity, strength and functionality, in addition to health education for their caregivers and family members.

If you decide to participate, the Consent Form will be signed and then you will undergo a physical therapy evaluation, with non-invasive tests to observe the functional physical capacity, the level of fatigue, the occurrence of pain and also the cognitive level.

Participants will be randomly allocated into two groups: the control group (CG) and the experimental group (EG). EG participants and their caregivers will receive a guideline with type, frequency, and duration of exercises. In addition, they will have weekly remote monitoring (1 time a week), via telephone contact, by the study therapists. Those in the CG will also receive the guideline, and will have weekly follow-up (once a week) in person, with home visits from the study therapists.

The reevaluation will be carried out every 2 months with the application of specific questionnaires remotely, through video calling platforms. Risk prediction is related to possible constraints when answering questions that reinforce awareness of restricted and disabling physical conditions; you may also experience dyspnea (respiratory discomfort) from answering questions over a period of time. To minimize the risks, researchers will, at the beginning of each assessment, make you aware of answering questions calmly, without haste; you will not be required to answer questions that make you uncomfortable and/or uncomfortable; you can take breaks anytime you feel tired and we will also ask the caregiver/companion for assistance in answering questions if necessary. We will also use secure platforms in the case of questionnaires and we will follow the provisions of the General Law for the Protection of Personal Data (No. 13.709) to protect your personal data.

The possible benefits will be included in the assessment and physical therapy guidelines that will be given to each case in a specific way, in addition to helping health professionals and the scientific community to clarify the process of motor evolution of the condition; give support

to physiotherapists in the development of motor and treatment plans; as a result, assist in research and technologies related to physical therapy assistance in ALS. You are free to opt out of the survey at any time without any prejudice or coercion, and the assistance provided by the multi-professional team is guaranteed .

If you have any problem related to the research, you will be entitled to free assistance that will be provided through physical therapy care by the responsible researchers.

During the entire period of the research, you can clear up your doubts by calling physiotherapist Aline Alves de Souza through contact: (84) 99819-8935 or at the Federal University of Rio Grande do Norte: Avenida Senador Salgado Filho, number 3000.

The data you provide us will be confidential and will only be disclosed at conferences or scientific publications, with no data that might identify you being disclosed.

These data will be kept by the responsible researcher in a safe place and for a period of 5 years. If there is any expense for your participation in this research, it will be borne by the researcher and reimbursed to you. If you suffer any proven damage as a result of this research, you will be indemnified.

If you have any questions about the ethics of this research, you should contact the Research Ethics Committee of the Onofre Lopes University Hospital, telephone: (84) 3342-5027, address: Av. Nilo Peçanha, 620, Petrópolis – Teaching and Education Management. Survey – Administrative Building – 3rd floor, Natal/RN. gep_huol@outlook.com.

This document was printed in two copies. One will stay with you and the other with the responsible researchers.

Patient Consent Form

After having been clarified about the objectives, importance and how the data will be collected in this research, in addition to knowing the risks, discomforts and benefits it will bring to me and having been aware of all my rights, I agree to participate in the research “Project RevELA: Effects of a home-based exercise protocol with remote and face-to-face monitoring of individuals with Amyotrophic Lateral Sclerosis: randomized clinical trial”, and I authorize the disclosure of information provided by me in conferences and/or scientific publications as long as no data can identify me.

Signature of research participant

Statement by the responsible researcher

As the researcher responsible for the study "Project RevELA: Effects of a home-based exercise protocol with remote and face-to-face monitoring of individuals with Amyotrophic Lateral Sclerosis: randomized clinical trial ", I declare that I assume full responsibility for faithfully complying with the methodological procedures that have been clarified and guaranteed to the participant of this study, as well as to keep the identity of the same confidential.

I also declare that I am aware that, if I fail to comply with the commitment hereby assumed, I will be violating the norms and guidelines proposed by Resolution 466/12 of the National Health Council - CNS, which regulates research involving human beings.

Signature of the Researcher